Table 4.
Laboratory and clinical characteristics of JAK2V617F positive PV patients from validation cohort stratified by their variant allele frequency (VAF > / ≤ 50%).
| Laboratory and clinical characteristics | All patients (n = 289) | JAK2 V617F VAF ≤ 50% (n = 143; 49.5%) | JAK2 V617F VAF > 50 % (n = 146; 50.5%) | P values* |
|---|---|---|---|---|
| Age in year; median (range) | 61 (19–89) | 60 (21–89) | 62 (19–89) | 0.67 |
| Age ≥ 60 years; n (%) | 150 (51.9) | 72 (50.3) | 78 (53.4) | 0.60 |
| Sex females; n (%) | 146 (50.5) | 68 (47.6) | 78 (53.4) | 0.31 |
| Risk stratification; high risk n (%) | 167 (57.8) | 81 (56.6) | 86 (58.9) | 0.69 |
|
White blood cells x 109/L; median (range) N evaluable=245 |
10.05 (1.0–25.2) | 9.6 (5.3–22.8) | 10.2 (1.0–25.2) | 0.02 |
|
White blood cells ≥ 11 ×109/L; n (%) N evaluable=245 |
86 (35.1) | 38 (30.2) | 48 (40.3) | 0.09 |
| Hemoglobin, g/dL; median (range) | 17.1 (12.1–24.0) | 16.8 (13.9–21.2) | 17.4 (12.1–24.0) | 0.0085 |
| Hematocrit, % median (range) | 52.9 (40.6–71.0) | 51.6 (41.5–66.0) | 54.4 (40.6–71.0) | 0.0001 |
|
Platelets x 109/L; median (IQR) N evaluable =251 |
503 (368.5–647.0) | 550 (412.0–695.7) | 443 (334.0–599.0) | 0.0009 |
|
Palpable splenomegaly; n (%) N evaluable =276 |
97 (35.1) | 39 (27.3) | 58 (42.3) | 0.013 |
|
Constitutional symptoms; n (%) N evaluable =283 |
33 (11.7) | 14 (9.9) | 19 (13.5) | 0.03 |
|
Pruritus; n (%) N evaluable =283 |
110 (38.9) | 48 (33.8) | 62 (44.0) | 0.08 |
| Arterial thrombosis before/at diagnosis; n (%) | 50 (17.3) | 27 (18.9) | 23 (15.7) | 0.48 |
| Arterial thrombosis at follow-up; n (%) | 45 (15.6) | 20 (14.0) | 25 (17.1) | 0.46 |
| Venous thrombosis before/at diagnosis; n (%) | 36 (12.5) | 17 (11.9) | 19 (13.0) | 0.77 |
| Venous thrombosis at follow-up; n (%) | 43 (14.9) | 11 (7.7) | 32 (21.9) | 0.0006 |
| Major bleeding at follow-up; n (%) | 32 (11.1) | 15 (10.5) | 17 (11.6) | 0.75 |
| Cardiovascular risk factors; n (%) | 184 (63.7) | 97 (67.8) | 87 (59.6) | 0.14 |
| Microcirculatory symptoms; n (%) | 111 (38.4) | 58 (40.6) | 53 (36.3) | 0.46 |
| MF progression; n (%) | 23 (7.9) | 4 (2.8) | 19 (13.0) | 0.0013 |
| AML progression: n (%) | 5 (1.7) | 2 (1.4) | 3 (2.1) | 0.67 |
| Death; n (%) | 19 (6.6) | 4 (2.8) | 15 (10.3) | 0.0028 |
| Median survival (years) | Not reached | Not reached | 25.7 | 0.13 |
*significant p values highlighted in bold refer to comparison of ≤50% and >50%.